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The links between viruses and cancer have been extensively invest-
igated (zur Hausen, 1991). Epstein–Barr virus (EBV) was the first
virus shown to contribute to major cell proliferation disorders in
humans. EBV was initially detected in neoplasic cells of endemic
Burkitt’s lymphoma (BL), undifferentiated nasopharynx carci-
noma (NPC), then in Hodgkin’s disease. The few data available on
EBV in breast tumours are conflicting (Chang et al, 1992; Gaffey
et al, 1993; Horiuchi et al, 1994; Labrecque et al, 1995;
Lespagnard et al, 1995; Glaser et al, 1998; Bonnet et al, 1999;
Brink et al, 2000). 
EBV is a g-herpesvirus. Latent products of its DNA genome
include highly abundant small transcripts (EBER 1 and 2) and
nuclear proteins (EBNA-1–6). Two types of EBV (EBV1 and
EBV2) have been identified based on the divergent sequences in
the EBNA genes. In vitro, EBV1 is the more strongly immortal-
izing of the types (Rickinson et al, 1987). 
Serological evidence shows that EBV infects most people early
in life and is generally carried in latent form by peripheral B
lymphocytes. In contrast, there are large geographical variations in
the prevalence of cancers with the strongest link to EBV (Parkin,
1986; De The, 1993). Endemic foci of NPC are found in the
Maghreb (Hubert et al, 1993; IARC, 1997), while the risk of 
NPC is low in northern Europe. The prevalence is intermediate in
southern France where migrants of Maghrebian origin and 
French people born in Maghreb represent more than 20% 
of the population (Jeannel et al, 1993; Bouchardy et al, 
1996). 
The aim of this study was to investigate the frequency and
genome load of EBV in a large series of breast cancers, alongside
possible geographical influences. On behalf of an international
study group we collected 509 primary invasive ductal breast
cancers from areas with varying risks of NPC. Different tech-
niques were used to assess the presence of EBV in these tumours,
including polymerase chain reaction (PCR) to amplify a subregion
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Summary Since the few data exploring a possible association between Epstein–Barr virus (EBV) and breast cancer are conflicting, we
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risk area); and northern Europe (northern France, the Netherlands and Denmark; low-risk areas). Polymerase chain reaction (PCR) of a
subregion of EBV BamHIC encoding the EBERs demonstrated that 31.8% of the tumours contained the viral genome. No significant
differences were observed among the geographical areas. However, positive samples showed higher loads of the EBV genome in the NPC
high- and intermediate-risk areas than in the low-risk areas. EBV type 1 was the dominant strain. In situ hybridization studies using a 35S-
labelled riboprobe for EBER1 and a laser capture microdissection, combined with quantitative PCR, showed that EBV localization was
restricted to some tumour epithelial cell clusters. EBV could not be detected in the stroma. Considering the whole population covered, the
presence of the EBV genome was not correlated with age, menopausal status, tumour, size, nodal status or histological grade. © 2001
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EBV subtype, in situ hybridization (ISH) of EBV ribonucleic acid
and laser capture microdissection (LCM), combined with quantit-
ative PCR (Q-PCR), to localize EBV. The clinical profiles of EBV-
negative and EBV-positive tumours were compared. 
MATERIALS AND METHODS 
Patients 
This study involved 509 primary invasive ductal breast carci-
nomas with clinical and pathological characteristics shown in
Table 1. 
NPC high-risk areas (Maghrebian countries) 
Patients from Algeria (n = 40) were recruited in Annaba and
Constantine, and patients from Tunisia (n = 58) were treated at the
Institut Salah Azaïz. Young patients and patients with inflammat-
ory carcinomas (Sobin and Wittekind, 1997) represented a large
proportion of these populations, as previously reported (Tabbane
et al, 1977; Tabbane et al, 1985). 
NPC intermediate-risk area (southern France) 
Patients from Marseille, France (n = 116) were treated at the
Clinique Bouchard and Hôpital de la Conception using similar
strategies. A high proportion (19.1%) of patients less than 35 years
old was selected. 
NPC low-risk areas (northern Europe) 
Patients from St Cloud, France (n = 72) were treated at the Centre
René Huguenin. Patients from The Netherlands (n = 126) under-
went primary surgery in or were referred to the Daniel den Hoed
Cancer Center in Rotterdam from 1981 to 1992 for adjuvant radio-
therapy; all the patients were node-positive and were included in a
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Table 1 Clinical and pathological characteristics 
Variable Total Algeria Tunisia Marseille St  Cloud Netherlands Denmark 
n = 509 n =4 0 n =5 8 n =1 1 6 n =7 2 n = 126 n =9 7
n1 % n1 % n1 % n1 % n1 % n1 % n1 % 
Age (years) 
#35 63 12.4 10 25.0 9 15.5 22 19.1 4 5.5 12 9.5 6 6.2 
(35–40) 79 15.6 9 22.5 14 24.2 21 18.3 8 11.1 20 15.9 7 7.2 
(40–50) 143 28.1 6 15.0 17 29.3 23 20.0 12 16.7 64 50.8 21 21.7 
(50–70) 182 35.8 15 37.5 17 29.3 28 24.3 36 50.0 30 23.8 56 57.7 
.70 41 8.1 0 0.0 1 1.7 21 18.3 12 16.7 0 0.0 7 7.2 
Hormonal status 
pre-menopausal 257 64.6 25 62.5 38 65.5 52 51.0 36 50.0 106 84.1 
post-menopausal 141 35.4 15 37.5 20 34.5 50 49.0 36 50.0 20 15.9 
Clinical tumour size 
T0 3 1.4 0 0.0 1 1.1 2 2.9 
T1 46 21.3 1 1.9 19 20.7 26 37.1 
T2 107 49.6 18 33.3 53 57.6 36 51.4
T3 45 20.8 26 48.1 14 15.2 5 7.2 
T4 15 6.9 9 16.7 5 5.4 1 1.4 
Clinical nodal status 
N0 117 53.9 5 9.1 55 60.4 57 80.3 
N1 88 40.6 42 76.4 33 36.3 13 18.3 
N2 10 4.6 6 10.9 3 3.3 1 1.4
N3 2 0.9 2 3.6 0 0.0 0 0.0 
Inflammatory status 
not inflammatory 476 95.6 30 75.0 35 74.5 116 100.0 72 100.0 126 100.0 97  100.0 
inflammatory 22 4.4 10 25.0 12 25.5 0 0.0 0 0.0 0 0.0 0 0.0 
Pathological tumor 
size (mm) 
<=20 128 28.9 2 3.7 48 46.6 34 47.9 39 30.9 5 5.6 
(20–50) 220 49.7 20 37.0 47 45.6 31 43.7 67 53.2 55 61.8 
>50 95 21.4 32 59.3 8 7.8 6 8.4 20 15.9 29 32.6 
Pathological nodal 
status 
negative 132 27.0 15 37.5 19 35.8 50 47.6 37 55.2 0 0.0 11 11.3 
positive 356 73.0 25 62.5 34 64.2 55 52.4 30 44.8 126 100.0 86 88.7 
0 117 26.1 19 35.8 50 47.6 37 55.2 0 0.0 11 11.3 
1–3 186 41.5 10 18.9 30 28.6 22 32.9 77 61.1 47 48.5 
>3 145 32.4 24 45.3 25 23.8 8 11.9 49 38.9 39 40.2 
Histological grade 
1 53 11.8 5 12.5 7 13.2 18 16.5 12 17.4 1 1.1 10 11.2 
2 211 47.0 32 80.0 28 52.8 46 42.2 35 50.7 15 16.9 55 61.8 
3 185 41.2 3 7.5 18 34.0 45 41.3 22 31.9 73 82.0 24 27.0 
n = number of patients. 1Owing to missing values, the number of patients does not always add up to the total number of patients in the analysed population. previous study (Romain et al, 1997). Patients from Denmark (n =
97) were registered in the high-risk group of the Danish Breast
Cancer Cooperative Group program (Andersen et al, 1981). 
Tissue specimens 
Breast tumour specimens were obtained at surgery and stored in
liquid nitrogen. Samples were all processed in Marseille (labora-
toire de Transfert d’Oncologie Biologique, Assistance Publique-
Hôpitaux de Marseille). Tumours from other areas were shipped
on solid carbon dioxide to this institution. Tumours were prepared
for DNA extraction (Sambrook et al, 1989) and cryosections.
Fixed paraffin-embedded tissues were obtained in specific cases,
according to the results of BamHIC PCR. 
PCR analysis of EBV genome 
Qualitative BamHIC PCR 
The synthetic primers, sense 5¢-AACCTCAGGACCTACGCT-3¢
and antisense 5¢-TAGCGGACAAGCCGAATAC-3¢, described by
Labrecque et al (1995), were used for BamHIC PCR. The ampli-
fied fragment is 501 base pair (bp). Aliquots of each PCR product
were electrophoresed on a 1% agarose gel in Tris/borate buffer
containing 0.5 mg ml–1 ethidium bromide, photographed, and
prepared for Southern blot (Sambrook et al, 1989). The filters were
hybridized with a random-primed 200 bp fragment of EBER1
cDNA (kindly provided by BE Griffin and LG Labrecque),
washed as previously described (Ouafik et al, 1989), and exposed
to film to verify the identity of the bands. 
Semi-quantitative BamHIC PCR 
To quantify the EBV genome load in the tumours, DNA extracted
from the Namalwa cell line, containing two integrated EBV copies
per cell, was used. 150 ´ 103 Namalwa cells yielded 1 mg of DNA.
Serial dilutions of DNA were prepared from 30.0 to 0.1 ng, equi-
valent to 9000-30 copies of EBV genome, respectively. Data are
expressed as the number of BamHIC copies/500 ng DNA. 
Real-time quantitative BamHIC PCR 
The 5¢-exonuclease (TaqMan) assay was used for real-time Q-PCR
(Bustin, 2000). Primers for BamHIC were: sense, 5¢-AAA-CAG-
GAC-AGC-CGT-TGC-C-3¢ (6935–6953); antisense, 5¢-AAG-
CCT-CTC-TTC-TCC-TTC-CCC-3¢ (7036–7016), and the probe
was FAM-TTT-CGG-ACA-CAC-CGC-CAA-CGC-T-TAMRA
(6961–6983). Amplification was performed in a 50 ml reaction
volume with a buffer consisting of 10 mmol l–1 Tris-HCl (pH 8.3;
25˚C), 50 mmol l–1 KC1, 10 mmol l–1 ethylenediamine tetraac-
etate, and 5 mmol l–1 MgCl2 in the presence of 200 mmol l–1 deoxy
(d)-ATP, dCTP and dGTP, 400 mmol l–1 dUTP, 200 nmol l–1 of each
primer, 200 nmol l–1 probe, 1 U Amp Erase UNG (Perkin-Elmer
Corp, Foster City, USA), and 1.25 U AmpliTaq Gold polymerase
(Perkin-Elmer Corp, Foster City, USA). BamHIC levels were
normalized to the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Primers for GAPDH were: sense, 5¢-CAA-ATT-CCA-
TGG-CAC-CGT-C-3¢ (3338–3356); antisense, 5¢-GCC-ACA-
CCA-TCC-TAG-TTG-C-3¢ (3471–3453), and the probe was
FAM-CCC-ATC-ACC-ATC-TTC-CAG-TAMRA (3392–3413).
PCR reactions were performed on a ABI Prism 7700 sequence
detection apparatus (Perkin Elmer Corp, Foster City, USA). The
cycling conditions for both BamHIC and GAPDH were as follows:
95˚C for 15 min; 45 cycles of 94˚C for 20 s, 55˚C for 20 s. Data
were expressed as the number of BamHIC copies/100 ng GAPDH. 
EBV genotyping 
The long divergent region of the EBNA-2 gene, reported for the
B95-8 (EBV1) and JiJoye (EBV2) cell lines (Buisson et al, 
1994), was used to select primers and probes for genotyping. 
BM1 5¢-CCACCAAGGCCTACCCGTCCT-3¢ and BM2 primers
5¢-GTGCTGCTGGTGGTGGCAAT-3¢ were used for both sub-
types EBV1 and EBV2. The amplified products were 262 bp for
EBV1 and 259 bp for EBV2. Amplification of DNA (1 mg) was
carried out as previously described (Buisson et al, 1994). The
internal oligonucleotides used as probe were 5¢-CGCATG-
CATCTCCCTGTCTT-3¢ for EBV1 and 5¢-CCACAAAGGCTCA-
CACTAGG-3¢ for EBV2. 
In situ hybridization (ISH) procedure 
Frozen and paraffin-embedded sections (10 mm) were used for
ISH studies. Paraffin-embedded sections were dewaxed in toluene,
rehydrated in graded ethanol, digested with 10 mg/ml proteinase K
(Roche Molecular Biochemicals, Meylan, France) for 30 min at
37˚C. Sections were mounted on subbed glass slides and prepared
for hybridization to RNA probes, as previously described (Ouafik
et al, 1990). Radiolabelled riboprobes were prepared using uridine
5¢-[a-35S-thio] triphosphate (Amersham Pharmacia Biotech,
Uppsala, Sweden) and T3 or T7 polymerase (Stratagene, La Jolla,
CA) to synthesize, respectively, RNA sense and antisense tran-
scripts of 200 bp EBER1 cDNA contained in pBluscript plasmid
(kindly provided by BE Griffin and LG Labrecque). Hybridized
sections were exposed to Ilford K5 autoradiography emulsion for a
variable length of time (1 week–1 month) to confirm the heterogen-
eous labelling patterns. 
Images were recorded using a PixCell II system (Arcturus
Engeneering, Mountain View, USA) which incorporates an
Olympus IX-50 microscope and a single sheep CCD colour
camera (COHU). Digitalization was performed via the colour
frame grabber Matrix MeteorTM slotted to a microcomputer. The
public domain software Image, written by W Rosbard at the
National Institute of Heath (NIH), was used for the image
processing. The mean grain density was quantified by morpholo-
gical filtering and thresholding, and expressed as percentage of
surface for both the tumour epithelial formations and the stroma. 
Laser capture microdissection 
OCT embedded tissue blocks prepared from frozen breast cancer
samples were sectioned at 8 mm in a cryostat. The sections mounted
on uncoated glass slides were fixed in 70% ethanol for 30 s,
stained with Mayer’s haematoxylin, and washed in 70% and 95%
ethanol for 60 s. Subsequently, slides were stained with eosin Y.
Staining was followed by two 60 s dehydration steps in 95% and
100% ethanol and two final 15 min dehydration steps in xylene.
Once air-dried, the sections were microdissected with a PixCell II
LCM system (Arcturus Engeneering, Mountain View, USA). For
each tumour analysed, several epithelial areas (approximatively 5
´ 103 cells) were independently captured; stromal areas without
infiltrating malignant epithelial cells were pooled to provide a
sufficient number of GAPDH copies. Cell populations were 
estimated to be homogeneous as determined by microscopic 
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subsequently used for Q-PCR. 
Statistical analysis 
Patients’ characteristics were compared with the Chi-square test. P
< 0.05 was considered significant. 
RESULTS 
PCR analysis of EBV genome 
In order to detect the presence of EBV genome in breast cancers,
genomic DNA was prepared and used for BamHIC PCR analysis.
A 501 bp amplified product was obtained (Figure 1). The presence
of the BamHIC subregion of the EBV genome was used to define
EBV positivity. Among the 509 breast cancers analysed, only
31.8% were EBV positive. The EBV-negative tumours included
samples shown with low, moderate and high degree of lympho-
plasmocytic infiltration by histopathology. In addition, normal
tissues adjacent to breast cancers (n = 3) and benign breast tumors
(n = 7), were investigated by PCR and were all found to be 
negative. 
Breast cancers showed a positive ratio from Algeria of 40.0%,
and from Tunisia 32.8%, Marseille 26.7%, St Cloud 29.2%, 
The Netherlands 32.5% and Denmark 35.1%, respectively.
Frequencies were not different among the geographical areas
studied. However, EBV-positive breast cancers from the NPC
high- and intermediate-risk areas showed higher loads of the EBV
genome than those from the low-risk areas: that is 47.0% and
28.1% of the samples contained more than 150 BamHIC
copies/500 ng DNA, respectively (P = 0.01) and 22.7% and 8.3%
more than 1500 BamHIC copies/500 ng DNA (P = 0.01) (Table 2). 
Detection of EBV genome and tumour characteristics 
In the overall population, no significant link was observed
between the detection of the EBV genome by BamHIC PCR and
age, menopausal status, tumour size and lymph node involvement.
No association was also demonstrated with histoprognostic grade;
in Marseille the highest EBV frequency was found in grade 3
(35.6%) and the lowest in grade 1 (22.2%), but differences were
not significant. The load of the EBV genome was also not correl-
ated with clinical and pathological characteristics. It is important
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Table 2 Frequency and load of EBV genome, as determined by qualitative and semi-quantitative BamHIC PCR respectively, in the overall population of breast
cancers and in breast cancers from different geographical areas 
EBV + tumours EBV + tumours with load of EBV  EBV + tumours with load of EBV 
genome >1504 genome >15004
Population % vs  %  vs  % vs  % vs  % vs 
all tumours all tumours EBV + tumours all tumours EBV + tumours
Total 31.8 (162/509) 11.4 (58/509) 35.8 (58/162) 4.5 (23/509) 14.2 (23/162) 
Algeria 40.0 (16/40) 17.5 (7/40) 43.8 (7/16) 10.0 (4/40) 25.0 (4/16) 
Tunisia 32.8 (19/58) 13.8 (8/58) 42.1 (8/19) 6.9 (4/58) 21.1 (4/19) 
Marseille 26.7 (31/116) 13.8 (16/116) 51.6 (16/31) 6.0 (7/116) 22.6 (7/31) 
St Cloud 29.2 (21/72) 11.1 (8/72) 38.1 (8/21) 4.2 (3/72) 14.3 (3/21) 
The Netherlands 32.5 (41/126) 11.9 (15/126) 36.6 (15/41) 4.0 (5/126) 12.2 (5/41) 
Denmark 35.1 (34/97) 4.1 (4/97) 11.8 (4/34) 0.0 (0/97) 0.0 (0/34) 
NPC high-risk areas1 35.7 (35/98) 15.3 (15/98) 42.9 (15/35) 8.2 (8/98) 22.9 (8/35) 
NPC intermediate-risk area2 26.7 (31/116) 13.8 (16/116) 51.6 (16/31) 6.0 (7/116) 22.6 (7/31) 
NPC high- and intermediate-risk areas 30.8 (66/214) 14.5 (31/214) 47.05  5 (31/66) 7.0 (15/214) 22.76  6 (15/66) 
NPC low-risk areas3 32.5 (96/295) 9.2 (27/295) 28.1 (27/96) 2.7 (8/295) 8.3 (8/96) 
1Algeria and Tunisia. 2Marseille. 3St Cloud, The Netherlands and Denmark. 4Expressed as the number of BamHIC copies/500 ng DNA. 5,6Significant difference
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Figure 1 Presence of EBV in breast cancers. DNA prepared from Namalwa
cell line (A) (from 30 ng to 0.1 ng) and breast cancer samples (200 ng) from
Algeria (B), Marseille (C; 7–11), Denmark (C; 12–17) was subjected to 38
cycles of PCR utilizing primers described under ‘Materials and Methods’.
Annealing was carried out at 56˚C for 30 s followed by extension at 68˚C for
35 s. The products were fractionated on a 1% agarose gel and prepared for
Southern blot analysis using a 200 bp DNA probe as described in ‘Materials
and Methods’. A control lacking DNA was subjected to PCR at the same time
(–). Samples 1, 2, 7, 8, 12, 13, 15: <150; 3, 4, 9, 14, 16, 17: 150–1500; 5, 6,
10, 11: >1500 BamHIC copies/500 ng DNA to point out that 40.0% of each inflammatory and non-inflammatory
Algerian samples were EBV positive; only inflammatory carci-
nomas (41.7% vs 28.6%) showed high rate of EBV positivity in
Tunisia. 
EBV genotyping 
EBV genotyping was applied to 13 breast cancers from Algeria,
Marseille, the Netherlands and Denmark containing more than 
150 BamHIC copies/500 ng DNA. EBV1 was present in all the
tumours examined. EBV2 was detected in 2 EBV1-positive
samples from the Netherlands (not shown). 
In situ hybridization 
20 EBV-positive breast cancers from Algeria, Tunisia and
Marseille were prepared for ISH studies in order to determine
whether EBV expression occurs in the tumour epithelial compart-
ment or in lymphoplasmocytic cells infiltrating the stroma. Positive
results were obtained on the malignant epithelial compartment of
those tumours with more than 1500 BamHIC copies/500 ng DNA
(n = 10). Considerable heterogeneity was however observed among
malignant epithelial areas. Heterogeneity was already detectable
using 1 week exposure and was still evident when the exposure
time was extended to 1 month. Figure 2A shows a section hy-
bridized with an antisense probe. Silver grains were concentrated
over the tumour epithelial formations, whereas the stroma
displayed fewer isolated grains; mean grain density was 9.4% and
1.7%, respectively. Such a pattern was considered to express the
specific localization of EBV material, since the close adjacent
section hybridized with the sense riboprobe, representative of the
technical background for the exposure time, also contained a low
density of randomly distributed silver grains both over the tumour
epithelial formations (1.9%) and the stroma (1.2%) (Figure 2B).
Figures 2C and 2D show two distant fields of the same highly
heterogeneous section hybridized with the antisense riboprobe. The
epithelial areas in field 2C contained a high density of silver grains
(9.5%) corresponding to EBV positivity whereas the low density
(1.8%) obtained in field 2D corresponds to negativity. For both
fields 2C (1.5%) and 2D (0.9%), a low grain density was observed
in the stroma. For the same tumours, signal intensity was lower in
paraffin-embedded sections than in cryosections. 
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Figure 2 In situ hybridization for EBV in breast cancer. Cryostat tumour sections (10 mm-thick) were hybridized with 35S-labelled antisense and sense
riboprobes, dipped in photographic emulsion, exposed for 1 month, developed, and lightly counterstained with haematoxylin. (A) shows a section hybridized
with the antisense riboprobe. Silver grains are concentrated over the tumour epithelial formations. A close adjacent section from the same tumour shown in (B), 
was hybridized with the sense riboprobe and displays a low density of randomly distributed silver grains. (C) and (D) show two distant fields of the same section
hybridized with the antisense riboprobe. The epithelial areas in field C contain a much higher density of silver grains compared to those in field (D). Calibration
bar for all micrographs = 50 mm 8 of the breast cancers, shown by PCR to be EBV negative were
examined by ISH and showed non-specific labelling. 
Laser microdissection combined with real-time
quantitative PCR 
In order to perform precise molecular analysis of purified cell
populations and determine whether EBV is localized in the stroma
or in the tumour epithelial compartment, as suggested by ISH, 
two EBV-positive breast cancers from Marseille were analysed
combining LCM and Q-PCR. Figure 3 shows a target tissue before
laser shots (Figure 3A) and the captured malignant epithelial cells
(Figure 3B). In both tumours some malignant epithelial areas 
were highly positive, with EBV loads ranging from 128 to 5816
BamHIC copies/100 ng GAPDH; however, other malignant
epithelial areas independently procured from the same case were
EBV-negative. GAPDH did not significantly differ between posit-
ive and negative epithelial areas. The stroma areas were EBV-
negative (Table 3). 
DISCUSSION 
Our results demonstrate that the EBV genome can be detected in
some breast cancers with a predominance of the EBV1 subtype.
Overall, 31.8% of our 509 tumour samples were positive for the
BamHIC non repetitive sequence. Labrecque et al (1995) reported
conservatively that 21% of breast cancers were positive for the
BamHIW repeat sequence, compared to 51% in Bonnet’s study
(1999). Elsewhere, absence of BamHIW has been reported in 10
medullary carcinomas (Lespagnard et al, 1995). In 37 tumours
analysed in the current study (not shown), the concordance
between BamHIC and BamHIW primer pairs for PCR analyses
was 83.7%. 
In our overall population, presence of the EBV genome was not
correlated with age, menopausal status, tumour size, nodal status,
or histological grade. In Marseille, there was however a trend
toward a positive association between EBV and grade, as reported
by Bonnet et al (1999). High rates of positive tumours were
observed in young Algerian patients and in inflammatory samples. 
The ISH using a 35S-labelled riboprobe for EBERs demon-
strated that EBV expression was exclusively localized in malig-
nant epithelial cells. The samples found strongly positive by 
PCR were also positive by ISH. Within individual tumours, a high
heterogeneity was however observed among epithelial cell clus-
ters. No labelling was obtained for samples that were negative by
PCR. In our study radioactive ISH signal intensities were low in
paraffin-embedded sections. The absence of labelling that has
been reported by others (Chang et al, 1992; Lespagnard et al,
1995; Glaser et al 1998) could be a result of technical problems,
such as the fixation as reported by Penault-Llorca et al (1994), or
of the low sensitivity of non-radioactive ISH. 
Laser capture microdissection (LCM) was combined with Q-
PCR to quantify the EBV genome in specific cell populations of
the tumours. This is the first time that this technique has been used
to localize EBV in breast cancers. The use of LCM clearly con-
firmed the epithelial localization of EBV and the heterogeneity
among epithelial cells, as suggested by ISH. The highest loads of
EBV genome found here in malignant epithelial populations
captured from EBV-positive breast cancers are in the median range
of those observed for NPC collected in Maghrebian countries,
when both are expressed as the number of BamHIC copies/100 ng
GAPDH (not shown). 
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Table 3 Load of EBV genome, as determined by real-time quantitative
BamHIC PCR in epithelial and stromal cell populations captured by laser
microdissection from two EBV-positive breast cancers 
Sample Cell population GAPDH1 EBV genome2
A Epithelium 11.3 5816 
A Epithelium 6.6 1956 
A Epithelium 35.4 128 
A Epithelium 7.1 0 
A Epithelium 19.3 0 
A Epithelium 33.1 0 
A Stroma 6.6 0 
B Epithelium 56.8 1532 
B Epithelium 19.3 403 
B Epithelium 29.0 272 
B Epithelium 6.6 0 
B Epithelium 14.8 0 
B Stroma 2.6 0 
1Expressed as the number of GAPDH copies. 2Expressed as the number of
BamHIC copies/100 ng GAPDH. 
AB
Figure 3 Laser capture microdissection (LCM) in breast cancer. Cryostat tumour sections (8 mm thick) stained with Mayer’s haematoxylin and eosin Y were
microdissected with the Arcturus Pixcell II system to procure homogeneous cell populations. A shows a section before LCM. B shows the malignant epithelial
cells captured by LCM. Calibration bar for all micrographs = 50 mm It is unlikely that our PCR-positive results are due to contamina-
tion. First, EBV was detected in 2 independent amplifications,
semi-quantitative PCR with Southern blot hybridization and Q-
PCR combined with LCM; secondly, Q-PCR was run in a closed-
tube system and required no post-amplification manipulation;
finally, normal human genomic DNA (Roche Molecular Bio-
chemicals, Meylan, France) and controls lacking DNA always
remained negative in PCR analyses. 
Detection of EBV in breast cancer has engendered a great deal
of controversy. In a recent note, Brink et al (2000) suggested that
positivity with EBV is most likely caused by the presence of some
infected lymphocytes in the tumour samples. However, it is
possible that the RT-PCR used by these authors was not sensitive
enough to detect all the EBV transcripts (Joab, 2000). In our study,
the presence of EBV in tumoral lymphoplasmocytic infiltration
can be ruled out. First, ISH demonstrated no specific labelling of
the stroma and the infiltrating lymphoplasmocytic cells near the
positive tumoral epithelial clusters; secondly, LCM combined with
Q-PCR also showed that EBV localization was restricted to some
tumour epithelial cell clusters; thirdly, the tumours found to be
EBV negative using BamHIC PCR included samples with low,
moderate, and high degrees of lymphoplasmocytic infiltration;
finally, EBV was not detected in normal tissues adjacent to breast
cancers and benign breast tumours, in agreement with previous
studies (Labrecque et al, 1995; Bonnet et al, 1999). 
One hypothesis mentioned by Labrecque et al (1995) for the
inconsistency concerning the presence of EBV in breast cancer is
that EBV-positive tumours might belong to a subgroup of breast
cancers. Our study shows that EBV frequencies were not different
among the geographical areas analysed. In contrast, the load of
EBV genome was significantly higher in NPC high-risk areas
(Maghrebian countries), and intermediate-risk areas (southern
France) where migrants of Maghrebian origin and French people
born in Maghreb account for a large proportion of the population.
Although differences in the patient characteristics among the
participating centres suggest that caution should be used in making
comparisons by country, environmental factors inherent to life style
and food habits that are not modified by migration, and inherit
susceptibility (Steinitz et al, 1990; Bouchardy et al, 1996; Parkin
and Iscovich, 1997), may partly explain the observed differences. 
In summary, we confirm the presence of EBV in breast cancers.
Our findings demonstrate that at least 31.8% of 509 samples of
invasive ductal carcinomas contain a subregion of BamHIC,
encoding EBERs, and that the load of intratumoral EBV genome
differs according to the geographical area. ISH and LCM studies
show that the EBV is located in some tumour epithelial cell clus-
ters, with no specific detection in lymphoplasmocytic infiltrations. 
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